557 related articles for article (PubMed ID: 34090959)
21. Janus kinase inhibitors: An innovative treatment for alopecia areata.
Park H; Yu DA; Kwon O
J Dermatol; 2019 Aug; 46(8):724-730. PubMed ID: 31237712
[TBL] [Abstract][Full Text] [Related]
22. Extended Safety Analysis of Baricitinib 2 mg in Adult Patients with Atopic Dermatitis: An Integrated Analysis from Eight Randomized Clinical Trials.
King B; Maari C; Lain E; Silverberg JI; Issa M; Holzwarth K; Brinker D; Cardillo T; Nunes FP; Simpson EL
Am J Clin Dermatol; 2021 May; 22(3):395-405. PubMed ID: 33826132
[TBL] [Abstract][Full Text] [Related]
23. Oral Baricitinib Restores Hair Loss in Alopecia Areata.
Slomski A
JAMA; 2022 Jun; 327(24):2386. PubMed ID: 35762995
[No Abstract] [Full Text] [Related]
24. Janus kinase inhibitors for alopecia areata.
King BA; Craiglow BG
J Am Acad Dermatol; 2023 Aug; 89(2S):S29-S32. PubMed ID: 37591562
[TBL] [Abstract][Full Text] [Related]
25. Baricitinib for the treatment of alopecia areata in adults: Real-world analysis of 36 patients.
Moreno-Vílchez C; Bonfill-Ortí M; Bauer-Alonso A; Notario J; Figueras-Nart I
J Am Acad Dermatol; 2024 May; 90(5):1059-1061. PubMed ID: 38246562
[No Abstract] [Full Text] [Related]
26. A Phase I/II Clinical Trial to evaluate the efficacy of baricitinib to prevent respiratory insufficiency progression in onco-hematological patients affected with COVID19: A structured summary of a study protocol for a randomised controlled trial.
Moreno-González G; Mussetti A; Albasanz-Puig A; Salvador I; Sureda A; Gudiol C; Salazar R; Marin M; Garcia M; Navarro V; de la Haba Vaca I; Coma E; Sanz-Linares G; Dura X; Fontanals S; Serrano G; Cruz C; Mañez R
Trials; 2021 Feb; 22(1):116. PubMed ID: 33546739
[TBL] [Abstract][Full Text] [Related]
27. Olumiant
Gupta AK; Wang T; Vincent K; Abramovits W
Skinmed; 2022; 20(6):452-455. PubMed ID: 36537681
[TBL] [Abstract][Full Text] [Related]
28. Reversal of Alopecia Areata Following Treatment With the JAK1/2 Inhibitor Baricitinib.
Jabbari A; Dai Z; Xing L; Cerise JE; Ramot Y; Berkun Y; Sanchez GA; Goldbach-Mansky R; Christiano AM; Clynes R; Zlotogorski A
EBioMedicine; 2015 Apr; 2(4):351-5. PubMed ID: 26137574
[TBL] [Abstract][Full Text] [Related]
29. Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-II).
Petri M; Bruce IN; Dörner T; Tanaka Y; Morand EF; Kalunian KC; Cardiel MH; Silk ME; Dickson CL; Meszaros G; Zhang L; Jia B; Zhao Y; McVeigh CJ; Mosca M
Lancet; 2023 Mar; 401(10381):1011-1019. PubMed ID: 36848919
[TBL] [Abstract][Full Text] [Related]
30. Janus kinase inhibitors for alopecia areata: A narrative review.
Haughton RD; Herbert SM; Ji-Xu A; Downing L; Raychaudhuri SP; Maverakis E
Indian J Dermatol Venereol Leprol; 2023; 89(6):799-806. PubMed ID: 37436019
[TBL] [Abstract][Full Text] [Related]
31. A Review of Safety Outcomes from Clinical Trials of Baricitinib in Rheumatology, Dermatology and COVID-19.
Bieber T; Feist E; Irvine AD; Harigai M; Haladyj E; Ball S; Deberdt W; Issa M; Grond S; Taylor PC
Adv Ther; 2022 Nov; 39(11):4910-4960. PubMed ID: 36063279
[TBL] [Abstract][Full Text] [Related]
32. Efficacy and Safety of Baricitinib Combined With Topical Corticosteroids for Treatment of Moderate to Severe Atopic Dermatitis: A Randomized Clinical Trial.
Reich K; Kabashima K; Peris K; Silverberg JI; Eichenfield LF; Bieber T; Kaszuba A; Kolodsick J; Yang FE; Gamalo M; Brinker DR; DeLozier AM; Janes JM; Nunes FP; Thyssen JP; Simpson EL
JAMA Dermatol; 2020 Dec; 156(12):1333-1343. PubMed ID: 33001140
[TBL] [Abstract][Full Text] [Related]
33. Effectiveness and safety of baricitinib in patients with alopecia areata: a systematic review and Meta-analysis of randomized controlled trials.
Mahmoud AM
Curr Med Res Opin; 2023 Feb; 39(2):249-257. PubMed ID: 36239359
[TBL] [Abstract][Full Text] [Related]
34. Janus Kinase Inhibitors in the Treatment of Alopecia Areata.
Stefanis AJ
Prague Med Rep; 2023; 124(1):5-15. PubMed ID: 36763827
[TBL] [Abstract][Full Text] [Related]
35. Baricitinib in patients with moderate-to-severe atopic dermatitis: Results from a randomized monotherapy phase 3 trial in the United States and Canada (BREEZE-AD5).
Simpson EL; Forman S; Silverberg JI; Zirwas M; Maverakis E; Han G; Guttman-Yassky E; Marnell D; Bissonnette R; Waibel J; Nunes FP; DeLozier AM; Angle R; Gamalo M; Holzwarth K; Goldblum O; Zhong J; Janes J; Papp K
J Am Acad Dermatol; 2021 Jul; 85(1):62-70. PubMed ID: 33600915
[TBL] [Abstract][Full Text] [Related]
36. Baricitinib (Olumiant) for severe alopecia areata.
Med Lett Drugs Ther; 2022 Sep; 64(1658):139-141. PubMed ID: 36094552
[No Abstract] [Full Text] [Related]
37. Efficacy and safety of ritlecitinib in adults and adolescents with alopecia areata: a randomised, double-blind, multicentre, phase 2b-3 trial.
King B; Zhang X; Harcha WG; Szepietowski JC; Shapiro J; Lynde C; Mesinkovska NA; Zwillich SH; Napatalung L; Wajsbrot D; Fayyad R; Freyman A; Mitra D; Purohit V; Sinclair R; Wolk R
Lancet; 2023 May; 401(10387):1518-1529. PubMed ID: 37062298
[TBL] [Abstract][Full Text] [Related]
38. Ritlecitinib: an investigational drug for the treatment of moderate to severe alopecia areata.
Eisman S; Sinclair R
Expert Opin Investig Drugs; 2021 Dec; 30(12):1169-1174. PubMed ID: 34826225
[TBL] [Abstract][Full Text] [Related]
39. A phase 2a randomized vehicle-controlled multi-center study of the safety and efficacy of delgocitinib in subjects with moderate-to-severe alopecia areata.
Mikhaylov D; Glickman JW; Del Duca E; Nia J; Hashim P; Singer GK; Posligua AL; Florek AG; Ibler E; Hagstrom EL; Estrada Y; Rangel SM; Colavincenzo M; Paller AS; Guttman-Yassky E
Arch Dermatol Res; 2023 Mar; 315(2):181-189. PubMed ID: 35230488
[TBL] [Abstract][Full Text] [Related]
40. Treatment of alopecia areata of the beard with baricitinib.
Moussa A; Eisman S; Sinclair RD; Bhoyrul B
J Am Acad Dermatol; 2023 Apr; 88(4):948-950. PubMed ID: 36427662
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
